Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2906-2912

  Koops, Heimen Schraffordt ^a   Vaglini, Maurizio ^a   Suciu, Stefan ^a   Kroon, Bin B R ^a   Thompson, John F ^a   Göhl, Jonas ^a   Eggermont, Alexander M M ^a   Di Filippo, Franco ^a   Krementz, Edward T ^a   Ruiter, Dirk ^a   Lejeune, Ferdy J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031697130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2906     Document Type: Article

References (30)

1. Klopp C, Alford T, Bateman J, et al: Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride: A preliminary report. Ann Surg 132:811-832, 1952
2. Creech O, Ryan R, Krementz ET: Treatment of malignant melanoma by isolation perfusion technique. JAMA 169:339-343, 1959
3. Luck J: Action of P-di(2-chloroethyl)-amino-L-phenylalanine on Harding Passey mouse melanoma. Science 123:984-985, 1956
4. Cavaliere R, Ciocatto E, Giovanella B, et al: Selective heat sensitivity of cancer cells: Biochemical and clinical studies. Cancer 20:1351-1381, 1967
5. Stehlin JS: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Oncol 129:305-308, 1969
6. Lejeune FJ, Deloof T, Ewalenko P, et al: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Rec Res Cancer Res 86:268-276, 1983
7. Storm FK, Morton DL: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 150:32-35, 1985
8. Santinami M, Belli F, Cascinelli N, et al: Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 42:201-208, 1989
9. Di Filippo F, Calabro A, Giannarelli D, et al: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63:2551-2561, 1989
10. Skene AI, Bulman AS, Williams TR, et al: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77:765-767, 1990
11. Klaase JM, Kroon B, van Geel AN, et al: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115:39-45, 1994
12. Thompson JF, Hunt JA, Shannon KF, et al: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132:903-908, 1997
13. Franklin HR, Schraffordt Koops H, Oldhoff J, et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 6:701-708, 1988
14. Schraffordt Koops H, Kroon BBR, Oldhoff J, et al: Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World J Surg 16:241-245, 1992
15. Wieberdink J, Benckhuysen C, Braat RP, et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910, 1982
16. Schraffordt Koops H: Surgical quality control in an international randomised clinical trial. Eur J Surg Oncol 18:525-529, 1992
17. Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1992
18. Machin D, Gardner MJ: Calculating confidence intervals for survival time analyses, in Gardem JM, Altmann DG (eds): Statistics With Confidence. Belfast, United Kingdom, University Press, 1989, pp 64-70
19. Balch CM, Murad TM, Soong SJ, et al: Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 43:883-888, 1979
20. Klaase JM, Kroon BB, van Geel AN, et al: The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: A comparison between an iliac and femoral perfusion procedure. Melanoma Res 2:407-410, 1992
21. Harrist TJ, Rigel DS, Day C Jr, et al: "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53:2183-2187, 1984
22. Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 200:764-768, 1984
23. Ghussen F, Kruger I, Groth W, et al: Randomized melanoma study of perfusion of the extremities. Results of treatment 2 1/2 years after premature discontinuation. German Chirurg 57:619-623, 1986
24. Ghussen F, Kruger I, Groth W, et al: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654-659, 1988
25. Veronesi U, Adamus J, Bandiera DC, et al: Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297:627-630, 1977
26. Sim FH, Taylor WF, Ivins JC, et al: A prospective randomized study of the efficacy of routine lymphadenectomy in the management of malignant melanoma. Cancer 41:948-956, 1978
27. Veronesi U, Adamus J, Bandiera DC, et al: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420-2430, 1982
28. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255-263, 1996
29. Lienard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992
30. Lienard D, Eggermont AM, Schraffordt Koops H, et al: Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1:21-26, 1994